Celcuity Inc. (CELC)
| Market Cap | 129.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.73M |
| Shares Out | 10.27M |
| EPS (ttm) | -0.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $12.60 |
| Previous Close | $11.75 |
| Change ($) | 0.85 |
| Change (%) | 7.23% |
| Day's Open | 11.99 |
| Day's Range | 11.73 - 12.86 |
| Day's Volume | 7,370 |
| 52-Week Range | 4.42 - 12.86 |
- UCLA Jonsson Comprehensive Cancer Center and Vanderbilt-Ingram Cancer Center will also participate - Study will evaluate the efficacy and safety of NERLYNX® and FASLODEX® in metastatic HR-po...
Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2020 Results - Earnings Call Transcript
Celcuity Inc. (CELC) CEO Brian Sullivan on Q2 2020 Results - Earnings Call Transcript
Celcuity Inc. (CELC) CEO Brian Sullivan on Q4 2019 Results - Earnings Call Transcript
While domestic economic growth has been benefiting small-cap stocks until now, you should consider selling some of the stocks before entering 2020 because of poor earnings growth projections.
Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2019 Results - Earnings Call Transcript
Celcuity, Inc. (CELC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
Celcuity's (CELC) CEO Brian Sullivan on Q2 2019 Results - Earnings Call Transcript
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
About CELC
Celcuity, a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It develops CELsignia HSF test to diagnose two new sub-types of HER2-negative breast cancer. The company is also developing CELsignia MP test to diagnose 11 cancer sub-types in breast, lung, colon, ovarian, k... [Read more...]
| Industry Diagnostics & Research | IPO Date Sep 20, 2017 |
| CEO Brian F. Sullivan | Employees 27 |
| Stock Exchange NASDAQ | Ticker Symbol CELC |
Analyst Forecasts
According to 2 analysts, the average rating for Celcuity stock is "Buy." The 12-month stock price forecast is 16.50, which is an increase of 30.95% from the latest price.